A CXCR4 inhibitor (balixafortide) enhances docetaxel‐mediated antitumor activity in a murine model of prostate cancer bone metastasis
Tyler Robinson(University of Michigan), Evan T. Keller(University of Michigan)
Cited by 20
Related Papers
Single-Cell Transcriptomics Analysis Identifies Nuclear Protein 1 as a Regulator of Docetaxel Resistance in Prostate Cancer Cells
|Molecular Cancer Research|2020|60
Targeted Notch1 inhibition with a Notch1 antibody, OMP‐A2G1, decreases tumor growth in two murine models of prostate cancer in association with differing patterns of DNA damage response gene expression
|Journal of Cellular Biochemistry|2019|13
Transcription factor network analysis based on single cell RNA-seq identifies that Trichostatin-a reverses docetaxel resistance in prostate Cancer
|BMC Cancer|2021|12
Dysregulated Ribosome Biogenesis Is a Targetable Vulnerability in Triple-Negative Breast Cancer: MRPS27 as a Key Mediator of the Stemness-inhibitory Effect of Lovastatin
|International Journal of Biological Sciences|2024|7
Spatial analysis reveals a novel inflammatory tumor transition state which promotes a macrophage-driven induction of sarcomatoid renal cell carcinoma
|bioRxiv (Cold Spring Harbor Laboratory)|2025|1